{"DataElement":{"publicId":"4449952","version":"1","preferredName":"Patient Central Nervous System Disease or Disorder Eligibility Determination Code Indicator","preferredDefinition":"The yes/no/not applicable coded response related to eligibility criteria for a person who receives medical treatment having disease related to the brain and spinal cord.","longName":"CNS_DX_EL_DT_CD_IND","context":"Theradex","contextVersion":"1","DataElementConcept":{"publicId":"2974446","version":"1","preferredName":"Patient Central Nervous System Disease or Disorder Eligibility Determination","preferredDefinition":"information related to eligibility criteria for person who receives medical attention, care, or treatment having disease related to the brain and spinal cord.","longName":"2233604v1.0:2974444v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2233604","version":"1","preferredName":"Patient","preferredDefinition":"A person who requires medical care.","longName":"C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D847-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2974478","version":"1","preferredName":"Central Nervous System Disease or Disorder Eligibility Determination","preferredDefinition":"The main information-processing organs of the nervous system, consisting of the brain, spinal cord, and meninges.:Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Criteria to determine eligibility of patients for medical care programs and services.","longName":"C12438:C2991:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Central Nervous System","conceptCode":"C12438","definition":"The part of the nervous system that consists of the brain, spinal cord, and meninges.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BD8A964-F208-8A21-E040-BB89AD436C37","latestVersionIndicator":"Yes","beginDate":"2009-12-29","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-12-29","modifiedBy":"ONEDATA","dateModified":"2009-12-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BD9A2C7-351D-7BDB-E040-BB89AD432FAC","latestVersionIndicator":"Yes","beginDate":"2009-12-29","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-12-29","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3298541","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"Indicator to represent a response of Yes, No, or Not Applicable._The affirmative response to a question or activity._The non-affirmative response to a question._Determination that a value is not relevant in the current context._A system of numbered categories for representation of data.","longName":"YES_NO_NA_CD_IND","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"1","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"X","valueDescription":"Not applicable","ValueMeaning":{"publicId":"2581003","version":"1","preferredName":"Not applicable","longName":"2581003v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0978-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":"2023.3.6 Added Alt VM-COG. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C223-0627-E040-BB89AD432C31","beginDate":"2002-02-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"N","valueDescription":"No","ValueMeaning":{"publicId":"2559515","version":"1","preferredName":"No","longName":"2559515","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B588-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C22D-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"},{"value":"Y","valueDescription":"Yes","ValueMeaning":{"publicId":"2560453","version":"1","preferredName":"Yes","longName":"2560453","preferredDefinition":"The affirmative response to a question or activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B932-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"CLOHNES","dateModified":"2023-09-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B04AC04D-C237-0627-E040-BB89AD432C31","beginDate":"2002-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3298540","version":"1","preferredName":"Yes No Not Applicable Code Indicator","preferredDefinition":"The affirmative response to a question or activity.:The non-affirmative response to a question.:Determination that a value is not relevant in the current context.:A system of numbered categories for representation of data.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"3298540v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C1F2-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"ONEDATA","dateModified":"2011-10-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CTMS:Clinical Trials Monitoring Service","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04AC04D-C203-0627-E040-BB89AD432C31","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-27","modifiedBy":"MAESKEB","dateModified":"2016-01-20","changeDescription":"Created to support Theradex design of CRFs for NCI CCR trials","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3876352","version":"1","longName":"Inclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876426","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"}]},{"publicId":"3876359","version":"1","longName":"Exclusion Criteria","context":"Theradex","ClassificationSchemeItems":[{"publicId":"10000083","version":"1","longName":"Physical & Concomitant Requirements","context":"Theradex"},{"publicId":"10000703","version":"1","longName":"Disease Status & Genetics","context":"Theradex"}]},{"publicId":"3876594","version":"1","longName":"Theradex","context":"Theradex","ClassificationSchemeItems":[{"publicId":"3876603","version":"1","longName":"Theradex - CTMS 3.14","context":"Theradex"}]}],"AlternateNames":[{"name":"NRG","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Theradex - 5","type":"Alternate Question Text","description":"Does patient have known brain metastases or carcinomatous meningitis?","url":null,"context":"Theradex"},{"name":"Theradex - 1","type":"Alternate Question Text","description":"Does patient have brain metastases that are symptomatic or untreated or not stable for greater than or equal to 3 months (must be documented by imaging) or requiring corticosteroids?","url":null,"context":"Theradex"},{"name":"Theradex - 3","type":"Alternate Question Text","description":"Does patient have known brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 4","type":"Alternate Question Text","description":"If patient has brain metastases and requires corticosteroids or non-enzyme inducing anticonvulsants, has dose of corticosteroids been stable and has been seizure free for 1 month prior to enrollment?","url":null,"context":"Theradex"},{"name":"Does patient have symptomatic","type":"Preferred Question Text","description":"Does patient have symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression?","url":null,"context":"Theradex"},{"name":"Theradex - 2","type":"Alternate Question Text","description":"Does patient have known brain metastases (even if treated)?","url":null,"context":"Theradex"},{"name":"Theradex - 8","type":"Alternate Question Text","description":"Does patient have active brain metastases or carcinomatous meningitis?","url":null,"context":"Theradex"},{"name":"Theradex - 16","type":"Alternate Question Text","description":"Does patient have untreated brain metastases, spinal cord compression, or evidence of symptomatic brain metastases or leptomeningeal disease as noted on computed tomography (CT) or magnetic resonance imaging (MRI) scans?","url":null,"context":"Theradex"},{"name":"Theradex - 7","type":"Alternate Question Text","description":"If patient has a history of CNS metastases, has patient received treatment and has either not had seizures or has been on stable doses of anti-seizure medicine and has had no seizures for 2 weeks?","url":null,"context":"Theradex"},{"name":"Theradex - 11","type":"Alternate Question Text","description":"Does patient have a primary brain tumor, active brain metastases or epidural disease?","url":null,"context":"Theradex"},{"name":"Theradex - 12","type":"Alternate Question Text","description":"If patient has central nervous system (CNS) metastases, are they stable after therapy for CNS metastases (such as surgery, radiotherapy or stereotactic radiosurgery) for at least 3 months and is off steroid treatment for 2 weeks prior to study enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 9","type":"Alternate Question Text","description":"Does patient have active brain metastases or leptomenigeal disease?","url":null,"context":"Theradex"},{"name":"Theradex - 14","type":"Alternate Question Text","description":"Does patient have active brain metastases or epidural disease?","url":null,"context":"Theradex"},{"name":"Theradex - 10","type":"Alternate Question Text","description":"If patient has known CNS involvement, is CNS disease cleared before treatment with Nivolumab, and there is no permanent CNS damage?","url":null,"context":"Theradex"},{"name":"Theradex - 13","type":"Alternate Question Text","description":"Does patient have known brain metastases or leptomenigeal disease?","url":null,"context":"Theradex"},{"name":"Theradex - 18","type":"Alternate Question Text","description":"Does patient have active or untreated brain metastases or leptomeningeal metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 17","type":"Alternate Question Text","description":"If patient has a history of CNS metastases, has patient received treatment and has either not had seizures or has been on stable doses of anti-seizure medicine and has had no seizures for 4 weeks?","url":null,"context":"Theradex"},{"name":"Theradex - 15","type":"Alternate Question Text","description":"Does patient have active CNS leukemia?","url":null,"context":"Theradex"},{"name":"Theradex - 21","type":"Alternate Question Text","description":"Does patient have symptomatic, uncontrolled brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 20","type":"Alternate Question Text","description":"Does patient have active brain disease including symptomatic brain metastases or the presence of leptomeningeal disease, or infraterntoiral tumors?","url":null,"context":"Theradex"},{"name":"Theradex - 19","type":"Alternate Question Text","description":"If patient has a prior history of brain metastases, have they been treated, patient is asymptomatic from the brain metastases and corticosteroids prescribed for management of the brain metastases have been discontinued at least 7 days prior to registration?","url":null,"context":"Theradex"},{"name":"Theradex - 22","type":"Alternate Question Text","description":"Does patient have symptomatic brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 23","type":"Alternate Question Text","description":"Does patient have presence of leptomeningeal carcinomatosis, greater than 1 cm mid-line shift, uncial herniation, significant hemorrhage/hydrocephalous or history of seizure?","url":null,"context":"Theradex"},{"name":"Theradex - 25","type":"Alternate Question Text","description":"Does patient have known or symptomatic, uncontrolled brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 24","type":"Alternate Question Text","description":"Does patient have leptomeningeal metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 45","type":"Alternate Question Text","description":"Does patient have greater than 1 cm mid-line shift, severe uncal herniation, or significant hemorrhage/hydrocephalous (intra-lesional hemorrhage is acceptable)?","url":null,"context":"Theradex"},{"name":"Theradex - 27","type":"Alternate Question Text","description":"Does patient have known, symptomatic/untreated brain/CNS metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 26","type":"Alternate Question Text","description":"Does patient have known brain metastases, known primary central nervous system (CNS) malignancy or symptomatic CNS metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 32","type":"Alternate Question Text","description":"Does patient have symptomatic central nervous system (CNS) metastases or leptomeningeal carcinomatosis?","url":null,"context":"Theradex"},{"name":"Theradex - 29","type":"Alternate Question Text","description":"Does patient have known primary central nervous system (CNS) malignancy or symptomatic CNS metastases, except as noted in the protocol?","url":null,"context":"Theradex"},{"name":"Theradex - 30","type":"Alternate Question Text","description":"Does patient have unstable brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 31","type":"Alternate Question Text","description":"Does patient have known primary central nervous system (CNS) malignancy or symptomatic CNS metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 28","type":"Alternate Question Text","description":"If patient has asymptomatic untreated CNS disease are all of the following criteria are met: Evaluable or measurable disease outside the CNS,; No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm); No history of intracranial hemorrhage or spinal cord hemorrhage;  No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted; No neurosurgical resection or brain biopsy within 28 days prior to Cycle 1, Day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 33","type":"Alternate Question Text","description":"Does patient have known CNS metastases or seizure disorder (unless treated and stable for greater than or equal to 6 months without requirement for corticosteroids and without seizure activity)?","url":null,"context":"Theradex"},{"name":"Theradex - 35","type":"Alternate Question Text","description":"Does patient have untreated brain metastases, spinal cord compression, or leptomeningeal carcinomatosis?","url":null,"context":"Theradex"},{"name":"Theradex - 37","type":"Alternate Question Text","description":"Does patient have known brain metastases or carcinomatous meningitis?","url":null,"context":"Theradex"},{"name":"Theradex - 39","type":"Alternate Question Text","description":"Does patient have untreated brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 38","type":"Alternate Question Text","description":"Does patient have untreated central nervous system (CNS) involvement?","url":null,"context":"Theradex"},{"name":"Theradex - 40","type":"Alternate Question Text","description":"Does patient have known central nervous system involvement of myeloma?","url":null,"context":"Theradex"},{"name":"Theradex - 36","type":"Alternate Question Text","description":"Does patient have known active central nervous system (CNS) metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 50","type":"Alternate Question Text","description":"Does patient have known active or history of brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex 51","type":"Alternate Question Text","description":"If patient has central nervous system (CNS) metastases, are they stable after therapy for CNS metastases (such as surgery, radiotherapy or stereotactic radiosurgery) for at least 4 weeks and is off steroid treatment for 2 weeks prior to study enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 49","type":"Alternate Question Text","description":"Does patient have primary brain cancers or active CNS metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 53","type":"Alternate Question Text","description":"Does patient have symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression as documented by CT or MRI scan, analysis of cerebrospinal fluid or neurological exam?","url":null,"context":"Theradex"},{"name":"Theradex - 47","type":"Alternate Question Text","description":"Does patient have known active or history of brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 46","type":"Alternate Question Text","description":"Does patient have clinical evidence of leptomeningeal or brain metastases causing spinal cord compression that are symptomatic or untreated or not stable for greater than or equal to 4 weeks (must be documented by imaging) or requiring corticosteroids?","url":null,"context":"Theradex"},{"name":"Theradex - 41","type":"Alternate Question Text","description":"Does patient have known central nervous system involvement at the time of study entry?","url":null,"context":"Theradex"},{"name":"Theradex - 48","type":"Alternate Question Text","description":"Does patient have active brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 43","type":"Alternate Question Text","description":"Does patient have evidence of active disease in the central nervous system (CNS) defined as either the presence of active lesions on MRI obtained within 4 weeks of registration or progressive neurological decline?","url":null,"context":"Theradex"},{"name":"Theradex - 44","type":"Alternate Question Text","description":"Does patient have diffuse leptomeningeal carcinomatosis (focal/localized involvement is acceptable), greater than 1 cm mid-line shift, uncal herniation, or significant hemorrhage/hydrocephalous?","url":null,"context":"Theradex"},{"name":"Theradex - 54","type":"Alternate Question Text","description":"Does patient have known brain metastases with progressive neurologic dysfunction, requirement of steroids and lack of improvement on head imaging obtained prior to consent to this clinical trial or carcinomatosis meningitis?","url":null,"context":"Theradex"},{"name":"Theradex - 55","type":"Alternate Question Text","description":"Does patient have known malignant central nervous system (CNS) disease other than neurologically stable, treated brain metastases  defined as metastasis having no evidence of progression or hemorrhage for at least 2 weeks after treatment?","url":null,"context":"Theradex"},{"name":"Theradex - 58","type":"Alternate Question Text","description":"Does patient have known active central nervous system (CNS) involvement by lymphoma, including leptomeningeal involvement?","url":null,"context":"Theradex"},{"name":"Theradex - 57","type":"Alternate Question Text","description":"Does patient have known active brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 60","type":"Alternate Question Text","description":"Does patient have symptomatic central nervous system (CNS) metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 59","type":"Alternate Question Text","description":"Does patient have active CNS disease?","url":null,"context":"Theradex"},{"name":"Theradex - 56","type":"Alternate Question Text","description":"Does patient have diffuse lepto or pachy meningeal carcinomatosis (focal/localized involvement from limited meningeal based metastases are acceptable), greater than 1 cm mid-line shift, uncal herniation, or severe hemorrhage/hydrocephalous?","url":null,"context":"Theradex"},{"name":"Theradex - 63","type":"Alternate Question Text","description":"If patient has a history of brain/CNS metastases, are all of the following criteria met: Brain/CNS metastases  have been treated, there is no evidence of disease progression for greater than or equal to 3 months before the first dose of study drug, no hemorrhage after treatment, off-treatment with dexamethasone for 4 weeks before administration of the first dose of TAK-228 and no ongoing requirement for dexamethasone or anti-epileptic drugs?","url":null,"context":"Theradex"},{"name":"Theradex - 62","type":"Alternate Question Text","description":"Does patient have known cerebral or meningeal involvement by lymphoma?","url":null,"context":"Theradex"},{"name":"Theradex - 66","type":"Alternate Question Text","description":"If is registered to the randomized Phase II portion, does patient have brain metastases or a history of brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 65","type":"Alternate Question Text","description":"Does patient have active cerebral or meningeal involvement by lymphoma?","url":null,"context":"Theradex"},{"name":"Theradex - 64","type":"Alternate Question Text","description":"Does patient have known brain metastases or carcinomatous meningitis, except for patients whose brain metastatic disease status has remained stable for greater than or equal to 1 month after treatment of the brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 61","type":"Alternate Question Text","description":"Does patient have symptomatic uncontrolled brain metastases or known uncontrolled brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 69","type":"Alternate Question Text","description":"Does patient have known brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 68","type":"Alternate Question Text","description":"Does patient have central nervous system (CNS) involvement or known brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 67","type":"Alternate Question Text","description":"If registered to the randomized Phase II portion, does patient have brain metastases or a history of brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 71","type":"Alternate Question Text","description":"Does patient have active disease in the central nervous system (CNS) defined as either the presence of active lesions on MRI obtained within 4 weeks of registration or progressive neurological decline?","url":null,"context":"Theradex"},{"name":"Theradex - 72","type":"Alternate Question Text","description":"Does patient have untreated or symptomatic brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 73","type":"Alternate Question Text","description":"Does patient have untreated central nervous system (CNS) metastases or leptomeningeal carcinomatosis","url":null,"context":"Theradex"},{"name":"Theradex - 74","type":"Alternate Question Text","description":"Does patient have documented active central nervous system (CNS) involvement by leukemia or known brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 77","type":"Alternate Question Text","description":"If patient has symptomatic CNS metastases, are they neurologically unstable?","url":null,"context":"Theradex"},{"name":"Theradex - 75","type":"Alternate Question Text","description":"Does patient have known central nervous system involvement?","url":null,"context":"Theradex"},{"name":"Theradex - 76","type":"Alternate Question Text","description":"Does patient have known central nervous system (CNS) metastases or leptomeningeal metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 78","type":"Alternate Question Text","description":"If patient has  asymptomatic untreated CNS disease are all of the following criteria are met: Evaluable or measurable disease outside the CNS: No metastases to brain stem, midbrain, pons, medulla, cerebellum; No history of intracranial hemorrhage or spinal cord hemorrhage;  No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted; No neurosurgical resection or brain biopsy within 28 days prior to Cycle 1, Day 1?","url":null,"context":"Theradex"},{"name":"Theradex - 79","type":"Alternate Question Text","description":"Does patient have known central nervous system (CNS) involvement, new or progressive brain metastases or symptomatic CNS leukemia?","url":null,"context":"Theradex"},{"name":"Theradex - 83","type":"Alternate Question Text","description":"Does patient have primary CNS tumors, e.g., glioma?","url":null,"context":"Theradex"},{"name":"Theradex - 81","type":"Alternate Question Text","description":"Does patient have known, untreated or unstable brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 82","type":"Alternate Question Text","description":"Does patient have active central nervous system (CNS) or leptomeningeal disease at enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 34","type":"Alternate Question Text","description":"Does patient have symptomatic brain metastases or symptomatic leptomeningeal disease?","url":null,"context":"Theradex"},{"name":"Theradex - 84","type":"Alternate Question Text","description":"Does patient have symptomatic uncontrolled CNS disease?","url":null,"context":"Theradex"},{"name":"Theradex - 85","type":"Alternate Question Text","description":"If patient has a history of treated brain metastases, are all of the following criteria met prior to enrollment in the Phase 1 portion of the trial: there is no evidence of disease progression symptomatically and by imaging within 28 days prior to registration and patient is off steroids?","url":null,"context":"Theradex"},{"name":"Theradex - 86","type":"Alternate Question Text","description":"Does patient have untreated/uncontrolled CNS/leptomeningeal disease?","url":null,"context":"Theradex"},{"name":"Theradex - 42","type":"Alternate Question Text","description":"Does patient have known active and untreated brain metastases, primary brain tumors or carcinomatous meningitis?","url":null,"context":"Theradex"},{"name":"Theradex - 89","type":"Alternate Question Text","description":"If patient has a history of CNS metastases are the following criteria met: disease outside the CNS is present; has recovered from acute toxicity associated with the treatment to less than or equal to CTCAE Grade 1 or baseline (with the exception of alopecia), with no requirement for escalating doses of corticosteroids over the past 7 days; if currently taking enzyme-inducing anticonvulsants (EIAC), must be transitioned to non-enzyme inducing anticonvulsants at least 14 days or 5 half-lives prior to the first dose of study medication; no presence of symptomatic or untreated leptomeningeal metastases or spinal cord compression?","url":null,"context":"Theradex"},{"name":"Theradex - 87","type":"Alternate Question Text","description":"Does patient have leptomeningeal disease or active untreated brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 88","type":"Alternate Question Text","description":"Does patient have known, untreated brain metastases or leptomeningeal metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 91","type":"Alternate Question Text","description":"Does patient have known active CNS disease and/or carcinomatous meningitis?","url":null,"context":"Theradex"},{"name":"Theradex - 92","type":"Alternate Question Text","description":"Does patient have spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms?","url":null,"context":"Theradex"},{"name":"Theradex - 90","type":"Alternate Question Text","description":"If patient has known malignant central nervous system (CNS) disease, have they been treated and patient is neurologically stable  defined as metastasis having no evidence of progression or hemorrhage for at least 2 weeks after treatment (including brain radiotherapy)?","url":null,"context":"Theradex"},{"name":"NRG_CRF_TEXT 1","type":"Alternate Question Text","description":"Does the patient have definitive leptomeningeal metastasis?","url":null,"context":"NRG"},{"name":"Theradex - 93","type":"Alternate Question Text","description":"If patient has CNS tumors, does disease have any of the following characteristics on imaging:  any evidence of uncal herniation or mass effect leading to severe midline shift; tumor greater than 6 cm in single maximal dimension, or tumor that in the opinion of the investigator shows significant mass effect?","url":null,"context":"Theradex"},{"name":"Theradex - 94","type":"Alternate Question Text","description":"Does patient have a primary brain tumor, active brain metastases or epidural disease?","url":null,"context":"Theradex"},{"name":"Theradex - 96","type":"Alternate Question Text","description":"Does patient have evidence of leptomeningeal metastases either by imaging or CNS fluid findings?","url":null,"context":"Theradex"},{"name":"Theradex - 95","type":"Alternate Question Text","description":"Does patient have known untreated brain metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 97","type":"Alternate Question Text","description":"Does patient have untreated central nervous system (CNS) metastases?","url":null,"context":"Theradex"},{"name":"NRG_eCRF_Text","type":"Alternate Question Text","description":"If the patient has brain metastasis, have the criteria in 3.4.1 been met?","url":null,"context":"NRG"},{"name":"Theradex - 101","type":"Alternate Question Text","description":"Does patient have known primary central nervous system (CNS) malignancy or symptomatic CNS metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 99","type":"Alternate Question Text","description":"If patient has a history of brain metastases, does a head CT with contrast or brain MRI done prior to enrollment in the study document stable disease?","url":null,"context":"Theradex"},{"name":"Theradex - 100","type":"Alternate Question Text","description":"Does patient have central nervous system involvement?","url":null,"context":"Theradex"},{"name":"NRG_CRF_TEXT 2","type":"Alternate Question Text","description":"Does patient have spinal cord compression or spinal intramedullary, brain, and/or visceral  metastases?","url":null,"context":"NRG"},{"name":"NRG_CRF_Text 3","type":"Alternate Question Text","description":"Does the patient have untreated or unstable brain metastases or cranial epidural disease?","url":null,"context":"NRG"},{"name":"Theradex - 6","type":"Alternate Question Text","description":"Does patient have untreated leptomeningeal or brain metastasis or requiring corticosteroids?","url":null,"context":"Theradex"},{"name":"Theradex - 102","type":"Alternate Question Text","description":"Does patient have known untreated or symptomatic brain or leptomeningeal metastases?","url":null,"context":"Theradex"},{"name":"Theradex - 80","type":"Alternate Question Text","description":"Does patient have known active CNS disease and/or carcinomatous meningitis before study enrollment?","url":null,"context":"Theradex"},{"name":"Theradex - 103","type":"Alternate Question Text","description":"Does patient have active brain metastases or carcinomatous meningitis?","url":null,"context":"Theradex"},{"name":"NRG_CRF_Text 4","type":"Alternate Question Text","description":"Does the patient have evidence of leptomeningeal disease?","url":null,"context":"NRG"},{"name":"Theradex - 105","type":"Alternate Question Text","description":"Does patient have active or previously treated central nervous system (CNS) metastasis?","url":null,"context":"Theradex"},{"name":"NRG_CRF_Text 5","type":"Alternate Question Text","description":"Evidence of leptomeningeal disease (LMD).","url":null,"context":"NRG"},{"name":"Theradex - 70","type":"Alternate Question Text","description":"Does patient have known central nervous system (CNS) disease (except for treated asymptomatic CNS metastases)?","url":null,"context":"Theradex"},{"name":"Theradex - 104","type":"Alternate Question Text","description":"Does patient have new or progressive brain metastases (active brain metastases) or leptomeningeal disease?","url":null,"context":"Theradex"},{"name":"Theradex - 106","type":"Alternate Question Text","description":"Does patient have symptomatic uncontrolled CNS disease?","url":null,"context":"Theradex"},{"name":"NRG CRF Text 1","type":"Alternate Question Text","description":"Does the patient have symptomatic and active brain metastases and/or leptomeningeal metastasis on CT and/or MRI imaging:","url":null,"context":"NRG"},{"name":"Theradex - 107","type":"Alternate Question Text","description":"Does patient have untreated/uncontrolled CNS disease?","url":null,"context":"Theradex"},{"name":"Theradex - 108","type":"Alternate Question Text","description":"Does patient have leptomeningeal metastases, more than 3 untreated central nervous system (CNS) metastases, untreated brain metastases measuring greater than 1cm, or requiring treatment-dose steroids (greater than 10 mg/day prednisone equivalents) for CNS-related symptoms?","url":null,"context":"Theradex"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Does patient have untreated or previously treated central nervous system (CNS) metastasis that has been stable for less than 6 weeks or not meeting any of the protocol defined criteria?","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Does the patient have primary CNS tumors (including ATRT) with involvement of the brainstem?","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"008C4FAD-BDFB-835A-E050-BB89AD432DFD","latestVersionIndicator":"Yes","beginDate":"2014-08-13","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2014-08-13","modifiedBy":"KUMMEROA","dateModified":"2024-02-16","changeDescription":"9591_Theradex_08.13.14_ghd","administrativeNotes":"2024.2.16 AQT added per ticket request CADSR0003416. ak 2023.8.2 AQT added per ticket request CADSR0002682. ak 2023.6.27 AQT added per ticket request CADSR0002556. ak","unresolvedIssues":null,"deletedIndicator":"No"}}